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Abstract
Background: Mood and anxiety symptoms in chronic hepatitis C (CHC) may be related to the
patient awareness of the diagnosis and prognosis, to side effects induced by interferon (IFN)-alpha
treatment, as well as to substance abuse. However, the observation of metabolic alterations in
patients with CHC has led to hypothesize a direct effect of hepatitis C virus (HCV) on brain
function. This study was aimed at elucidating whether CHC is associated with specific anxiety or
mood disorders independently of confounding factors.
Methods: Patient cohort: consecutive patients, 135 with CHC and 76 with chronic hepatitis B
(CHB). Exclusion criteria: previous treatment with IFN-alpha, co-infection with HCV and hepatitis
B virus, infection with human immunodeficiency virus, drug or alcohol abuse, or malignancies.
Controls: subjects without evidence of hepatitis randomly extracted from the database of a
previous epidemiological study; they were divided into two groups of 540 (332 males) and 304 (220
males) as controls for patients with CHC and CHB, respectively. The psychiatric diagnosis was
formulated by means of the Composite International Diagnostic Interview Simplified carried out by
a physician according to DSM-IV criteria.
Results: A higher lifetime prevalence of major depressive disorder (MDD) was observed among
CHC compared to CHB or controls. The risk of MDD was not statistically different between CHB
and controls. Both the CHC and CHB groups showed a significantly higher frequency of panic
disorder when compared to controls. No statistical differences were observed in the prevalence
of general anxiety disorder and social phobia when CHC or CHB were compared to controls.
Conclusion: The present study provides the first evidence of an association between CHC and
MDD, diagnosed on the basis of well-defined international criteria. This association is independent
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of treatment with IFN-alpha and is not influenced by substance or alcohol abuse. By contrast,
anxiety disorders do not appear to be specifically associated with CHC.
Background
Infection with hepatitis C virus (HCV) is a major public
health problem worldwide. Besides the late clinical seque-
lae of chronic liver disease, such as cirrhosis and hepato-
cellular carcinoma, a high prevalence of depressive and
anxiety symptoms has been reported [1,2]. Patients with
chronic hepatitis C (CHC) exhibit worse scores, compared
to controls, in health-related quality of life indices, which
tend to improve upon successful antiviral therapy [3].
Clinically, these subjects often complain of fatigue, lassi-
tude and impaired memory that do not correlate with the
severity of liver disease [4,5]. The high rate of mood and
anxiety symptoms in patients with CHC may be related to
the patient awareness of the diagnosis and prognosis
[6,7], to side effects induced by treatment with interferon
(IFN)-alpha, the most effective drug currently available
for treatment of HCV infection [8], as well as to past or
present substance abuse. However, the observation of
metabolic alterations in patients with histologically mild
chronic hepatitis C, compared with healthy subjects or
patients with chronic hepatitis B (CHB), has led to
hypothesize a direct effect of HCV on brain function
[9,10].
Until now, no studies have investigated the association
between hepatitis C and specific psychiatric disorders.
This study was aimed at elucidating whether hepatitis C is
associated with specific anxiety or mood disorders diag-
nosed by structured interviews on the basis of internation-
ally defined criteria. To rule out the confounding factors
due to substance (drug and alcohol) abuse or IFN-alpha
treatment, patients with such history were not included
into the study. The lifetime prevalence of affective disor-
ders was evaluated in a cohort of patients with CHB and
CHB, all of whom were drug-free and had never previ-
ously been treated with IFN, as well as in a control group
of subjects recruited from the general population. It was
assumed that the awareness of the disease condition and
the stress caused by its uncertain outcome constituted a
comparable condition in patients affected by CHB or
CHC. The results of our study provide the first evidence of
a significant association between affective disorders and
chronic hepatitis C.
Methods
The patient cohort included 211 consecutive treatment-
naïve patients with chronic hepatitis B or C seen at the
Liver Unit of the University Hospital in Cagliari (Italy)
between 2002 and 2004. Subjects who were previously
treated with IFN-alpha, co-infected with HCV and HBV, or
infected with human immunodeficiency virus were
excluded from the study; likewise, subjects with lifetime
cocaine, heroine and alcohol addiction, as well as with a
diagnosis of malignancies, were excluded. Prior to taking
part in the study, all the subjects gave their informed con-
sent. The patient cohort included 135 patients with CHC
(83 males and 52 females, mean age 50.7 ± 10.3) and 76
patients with CHB (55 males and 21 females, mean age
44.1 ± 12.1). The diagnosis of CHB and CHC was made
according to established criteria. As controls, we studied
844 subjects with no diagnosis of hepatitis, who were ran-
domly extracted from the database of an epidemiological
study of health conditions in Sardinia [11]. During this
survey, people were asked about their general well being,
presence of illness, consultation with physicians and med-
ical tests they underwent both routinely (e.g., work or
driver license eligibility) or for health problems.
The selection of the controls was performed from the
database of a previous epidemiological survey (1040 sub-
jects) by matching age and sex with the cases using a ran-
domized block design. A block was constructed for each
individual constituting the group of cases, that included
all eligible age- (± 4 years) and sex-matched controls
obtained from the database. Four individuals per block
were extracted for each single case, thus implying their
automatic exclusion from remaining blocks. The samples
of controls for patients with CHB and CHC were extracted
independently. Controls subjects were divided into two
groups of 540 (332 males and 208 females) and 304 (220
males and 84 females) subjects, who were used as controls
for patients with CHB and CHC, respectively.
The psychiatric diagnosis was formulated by means of an
interview carried out by the physician using the Compos-
ite International Diagnostic Interview (CIDI) in its simpli-
fied Italian version [11], a structured interview developed
under the aegis of the World Health Organisation (WHO)
with the aim of facilitating epidemiological and clinical
studies. The computerised algorithm linked to the inter-
view facilitates the formulation of psychiatric diagnoses
according to criteria established by DSM-IV (APA 1994
[12]. Cases were interviewed at the Center for Liver Dis-
ease and controls in their own homes, as described in pre-
viously published studies [11].
Data analysis
Lifetime prevalence for DSM-IV [12] Major Depressive
Disorder, Generalized Anxiety Disorder, Panic Disorder,
Social Phobia was calculated in both cases (CHB andClinical Practice and Epidemiology in Mental Health 2007, 3:22 http://www.cpementalhealth.com/content/3/1/22
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CHC) and controls groups; the Odds Ratio association
(univariate analysis) for DSM-IV diagnosis (dependent
variable) was calculated using the two controls group as
"pivot". Statistical significance was calculated using the χ2
test in 2 × 2 tables. Odds Ratio confidence intervals were
calculated through application of the method of Miet-
tinen [13].
Results
The case groups included 135 patients with CHC (83
males and 52 females, mean age 50.7 ± 10.3) and 76
patients with CHB (55 males and 21 females, mean age
44.1 ± 12.1); the control group for CHC included 540
subjects (332 males and 208 females, mean age 50.1 ±
11.2); the control group for CHB included 304 subjects
(220 males and 84 females, mean age 44.8 ± 13.5). Data
analysis revealed a significantly higher number of lifetime
diagnoses of MDD among patients with CHC compared
to controls (32.6% vs 12.8%; χ2 = 29.0; p < 0.0001, 1DF,
OR = 3.3, CI 95% from 2.1 to 5.1). On the contrary, the
risk of MDD was not statistically different between sub-
jects with CHB and controls (17.1% vs 13.8%; χ2 = 0.30,
P = 0.58, OR = 1.3, CI 95% from 0.5 to 3.3) (Table 1).
Direct comparison between patients with CHC and CHB,
after standardisation by sex and age (<45 and >44) with a
total of 4 cells and with hepatitis C as a standard sample,
demonstrated a significantly higher frequency in the life-
time prevalence of MDD in hepatitis C (32.6% vs 15.1%,
χ2 = 6.7, P = 0.009, OR = 2.7, CI 95% from 1.3 to 5.9).
Regarding anxiety disorders, both groups of patients
showed a significantly higher lifetime prevalence of panic
disorder when compared to controls (for hepatitis C,
8.9% vs 2.8% in controls, χ2 = 8.9, P = 0.003, OR = 3.4, CI
95% from 1.5 to 7.5, Table 2; for hepatitis B, 7.9% vs 2.0%
in controls, χ2 = 5.1, P = 0.023, OR = 4.2, CI 95% from 1.2
to 14.4, Table 1).
No statistical differences were observed in the incidence of
generalised anxiety disorder (GAD) and social phobia
(SP) when patients with chronic hepatitis C or hepatitis B
were compared to controls.
Discussion
The present study provides the first evidence that chronic
hepatitis C is associated with major depressive disorders,
diagnosed on the basis of well-defined international crite-
ria. Furthermore, our findings demonstrate that this asso-
ciation is independent of treatment with IFN-alpha and is
not influenced by substance or alcohol abuse. In fact,
these confounding factors were ruled out by the selection
criteria of the study. Of note, we failed to find an associa-
tion between anxiety disorders and hepatitis C. Among
anxiety disorders, only panic disorders were more fre-
quent in patients with CHC than in controls, although
they were common also in patients with CHB. Thus, our
data suggest that anxiety disorders are not a specific con-
sequence of CHC, but rather reflect the stress associated
with the awareness of a chronic progressive disease or, in
other patient series, alternative risk factors such as drug or
alcohol abuse.
The observations reported in the literature about the com-
promised quality of life among patients affected by CHC,
regardless of the severity of the disease [1-3], lead to
hypothesize that HCV may exert a direct effect on brain
function [4]. Recent studies performed by means of ques-
tionnaires concerning the quality of life revealed a high
frequency of neurocognitive abnormalities in subjects
infected with HCV, both before and during treatment
[14,15]. Proton magnetic resonance spectroscopy (H-
MRS), a technique that provides information on the brain
metabolism, revealed clear anomalies in brain metabo-
lites in vivo in chronic hepatitis C patients [9].
Through application of P300-evoked potentials, a neuro-
physiological test used to assess the cognitive function,
Kramer and co-workers reported that approximately 17%
of HCV-infected patients presented abnormal P300
potentials [15]. Modifications of H-MRS and P300-
evoked potentials similar to those described above have
Table 1: Lifetime psychiatric diagnoses in a cohort of patients with chronic hepatitis B and in the control group
Major Depression Generalized Anxiety Disorder Panic Disorder Social Phobia
Chronic Hepatitis 13/76 7/76 6/76 3/76
B( % ) ( % ) ( % ) ( % )
17.1 9.2 7.9 3.9
Controls 42/304 38/304 6/304 16/304
(%) (%) (%) (%)
13.8 12.5 2.0 5.3
χ2 0.30 0.35 5.1 0.81
P 0.58 0.55 0.023 0.37
OR 1.3 0.7 4.2 0.7
CL 95% 0.5–3.3 0.2–2.3 1.2–14.4 0.3–1.5Clinical Practice and Epidemiology in Mental Health 2007, 3:22 http://www.cpementalhealth.com/content/3/1/22
Page 4 of 4
(page number not for citation purposes)
been widely reported in patients infected with HIV [16-
19] a virus that was conclusively shown to infect the cen-
tral nervous system (CNS). These studies are consistent
with the hypothesis that HCV may also be capable of
infecting the CNS causing neurological alterations or
damage [20]. In spite of the discrepancies present in the
literature with regard to the extrahepatic replication of
HCV, general consensus seems to exist on the capability of
this virus to infect mononuclear cells in peripheral blood
and bone marrow [21]. This suggests that monocytes or
progenitor cells infected by HCV may introduce the virus
into the CNS by means of a "Trojan Horse" mechanism,
inducing neuronal dysfunction. This hypothesis is sup-
ported by the recent finding of HCV genetic sequences in
brain tissue at post-mortem examination [22].
In conclusion, the significant association that we docu-
mented between an important psychiatric disorder such
as major depressive disorder and chronic hepatitis C in
patients who had not been treated previously with IFN
and with no history of substance abuse adds ground to the
hypothesis that this mood disorder is a direct manifesta-
tion of HCV infection. However, our findings are only pre-
liminary and further studies are warranted in order to
confirm the hypothesis of an increased risk of affective
disorders during chronic hepatitis C infection and eluci-
date their pathogenesis.
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